Related Experiment Video
Updated: Jun 4, 2025
08:40
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
Published on: April 8, 2016
12.7K
Differences in CD24 Expression Between Prostate Adenocarcinoma and Benign Prostatic Hyperplasia: A Cross-sectional
Mahdi Sajedifar1, Atieh Jafarabadi Ashtiani1, Mohammadreza Jalali Nadoushan2
1Student Research Committee, Faculty of Medicine, Shahed University, Tehran, Iran.
Iranian Journal of Pathology
|December 17, 2024
Summary
CD24 expression is significantly higher in prostate adenocarcinoma compared to benign prostatic hyperplasia. High CD24 levels correlate with higher Gleason scores, indicating potential for cancer progression.
Area of Science:
- Oncology
- Urology
- Biochemistry
Background:
- CD24 is a highly glycosylated membrane protein linked to cancer progression.
- Prostate adenocarcinoma, a common male cancer, relies on Gleason grading for prognosis.
- Investigating CD24's role in prostate cancer is crucial for understanding disease behavior.
Purpose of the Study:
- To examine the association between CD24 expression and benign prostatic hyperplasia (BPH).
- To determine the relationship between CD24 expression and Gleason grade in prostate adenocarcinoma.
- To evaluate CD24 as a potential biomarker in prostate cancer diagnosis and staging.
Main Methods:
- A cross-sectional study involving 163 patients undergoing prostate surgery.
- Immunohistochemical staining was employed to assess CD24 expression levels.
- Gleason grading was performed for prostate adenocarcinoma cases; statistical analysis used SPSS 22.
Main Results:
- CD24 expression (percentage and intensity) was significantly elevated in prostate adenocarcinoma versus BPH (P<0.05).
- Gleason score demonstrated a strong correlation with both the percentage and intensity of CD24 staining (P<0.05).
- The immunoreactive score for CD24 also showed a significant relationship with Gleason score (P<0.05).
Conclusions:
- CD24 expression serves as a distinguishing factor between prostate adenocarcinoma and BPH.
- Elevated CD24 levels may signify advanced prostate cancer progression.
- CD24 warrants further investigation as a prognostic marker in prostate cancer.
